ScoPo’s Powerplays: ASX health stocks up as Cochlear upgrades earnings guidance
Health & Biotech
1 hour ago | Nadine McGrath
Brisbane-based medical software technology company ImpediMed (ASX:IPD) has seen its share price fall ~20% in the past five days after release of its Q2 FY24 cashflow report which was below expectation.
Furthermore, IPD is still recovering from last year’s board stoush with new leadership including the appointment of Dr Parmjot Bains as managing director and interim CEO.
“They did report a weaker than expected second quarter result and with a new board and CEO in place they’re still getting themselves up to speed,” Power says.
“The new team has a bit of work to do to regain confidence of the shareholder base but I am sure they will.”
ScoPo’s Powerplays: ASX health stocks up as Cochlear upgrades...
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $161.8M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 115638 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 91495 | 2 |
View Market Depth
| Last trade - 07.00am 03/05/2024 (20 minute delay) ? |
| IPD (ASX) Chart |
Day chart unavailable